<DOC>
	<DOC>NCT00754650</DOC>
	<brief_summary>This single arm study evaluated the bone marrow response, safety, and tolerability of 6 months treatment with Avastin (bevacizumab) monotherapy in patients with chronic lymphocytic leukemia. Patients received 8 cycles (21 days duration) of Avastin monotherapy (15mg/kg) with 6 months of follow-up.</brief_summary>
	<brief_title>A Proof of Concept Study of the Safety, Tolerability, and Efficacy of Avastin (Bevacizumab) in Patients With Chemo-naive Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Male or female patients, ≥ 18 years of age. Bchronic lymphocytic leukemia not yet requiring treatment. Eastern Cooperative Oncology Group (ECOG) performance status 02. No previous treatment of chronic lymphocytic leukemia (CLL) by chemotherapy, radiotherapy, or immunotherapy. Life expectancy &gt; 6 months. Central nervous system (CNS) involvement by lymphoma or any evidence of spinal cord compression. Computed tomography (CT) scan based evidence of tumor invading major blood vessels. Gastrointestinal (GI) tract involvement by CLL. Active viral, bacterial, or fungal infection. Uncontrolled hypertension, cerebrovascular accident/stroke (≤ 6 months prior to randomization), myocardial infarction (≤ 6 months prior to randomization), unstable angina (≥ New York Heart Association (NYHA) Grade IV), thrombosis within 6 months before enrollment, NYHA Grade II congestive heart failure, or serious cardiac arrhythmia requiring ongoing medication.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>